Compare RPID & CRBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | RPID | CRBU |
|---|---|---|
| Founded | 2006 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 178.6M | 203.9M |
| IPO Year | 2021 | 2021 |
| Metric | RPID | CRBU |
|---|---|---|
| Price | $3.37 | $1.65 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | $8.00 | ★ $9.33 |
| AVG Volume (30 Days) | 105.1K | ★ 973.8K |
| Earning Date | 11-07-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $30,523,000.00 | $9,295,000.00 |
| Revenue This Year | $19.36 | N/A |
| Revenue Next Year | $21.48 | $4.96 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 16.63 | N/A |
| 52 Week Low | $0.87 | $0.66 |
| 52 Week High | $4.50 | $3.54 |
| Indicator | RPID | CRBU |
|---|---|---|
| Relative Strength Index (RSI) | 37.43 | 33.24 |
| Support Level | $3.27 | $1.82 |
| Resistance Level | $3.69 | $1.91 |
| Average True Range (ATR) | 0.23 | 0.10 |
| MACD | -0.11 | -0.01 |
| Stochastic Oscillator | 12.24 | 1.52 |
Rapid Micro Biosystems Inc is an life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company's flagship Growth Direct platform automates and modernizes the antiquated, manual microbial quality control (MQC) testing workflows used in the pharmaceutical manufacturing operations across the globe. It derives revenue from development, manufacturing, marketing and selling Systems and related LIMS connection software, consumables and services.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.